RenovoRx (RNXT) said Wednesday that New York-based Northwell Health Cancer Institute started enrolling patients with advanced pancreatic cancer in an ongoing phase III trial that will evaluate the Trans-Arterial Micro-Perfusion therapy platform.
The study will use RenovoRx's TAMP therapy platform to evaluate its first drug-device combination product candidate, which is an intra-arterial infusion of gemcitabine via the RenovoCath delivery system. The study will compare treatment with TAMP versus the current standard-of-care chemotherapy, according to the company.
Shares of RenovoRx were up more than 4% in early morning trade.
Price: 1.16, Change: +0.05, Percent Change: +4.32
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。